Affinity DataKi: 0.0000150nMAssay Description:Inhibition of HIV1 proteaseMore data for this Ligand-Target Pair
Affinity DataKi: 0.0000570nMAssay Description:Inhibition of HIV1 protease by fluorescent peptide substrate based assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.00147nMAssay Description:Inhibition of HIV1 proteaseMore data for this Ligand-Target Pair
Affinity DataKi: 0.00800nMAssay Description:Inhibition of HIV1 protease by fluorescent peptide substrate based assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.0360nMAssay Description:Inhibition of HIV1 proteaseMore data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.260nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.330nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.370nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.390nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.410nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.420nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.450nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.460nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.470nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.480nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.490nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.520nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.520nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.530nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.530nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.540nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.540nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.550nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.570nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.590nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.600nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.600nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.630nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.640nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.660nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.660nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.690nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.690nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.700nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.710nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.720nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.720nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.730nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.75nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.790nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.790nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Homo sapiens (Human))
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.800nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair